Interim FDG-PET in Hodgkin lymphoma: A compass for a safe navigation in clinical trials?

Blood

Volumn 120, Issue 25, 2012, Pages 4913-4920

  Gallamini, Andrea ^a   Kostakoglu, Lale ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; NAVELBINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; STANDARDIZATION; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

EID: 84870999504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-403790     Document Type: Review

References (91)

1. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;2003: 225-247.
2. Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma N Engl J Med. 2009;361(24):2390-2391.
3. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkin's disease patients: report of 25 years of experience at the Milan cancer Institute. Eur J Cancer. 2005;41(7): 998-1006. (Pubitemid 40602851)
4. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma. 1999; 34(5):545-551. (Pubitemid 29429736)
5. Rigacci L, Castagnoli A, Carpaneto A, Carrai V, Vaggelli L, Matteini M. Can 18F-FDG PET after the first cycle chemotherapy predict the efficacy of therapy in Hodgkin's disease? Haematologica. 2002;87(5):ELT24.
6. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160-1168. (Pubitemid 41418320)
7. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59. (Pubitemid 43053523)
8. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91(4): 475-481.
9. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002; 43(8):1018-1027. (Pubitemid 34847924)
10. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107(11):2678-2687. (Pubitemid 44845624)
11. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol . 2006;17(8):1296-1300. (Pubitemid 44288221)
12. Terasawa T, Lau J, Bardet S, et al. Fluorine-18- fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906-1914.
13. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F]fluoro-2-deoxy-D glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian- Danish study. J Clin Oncol. 2007;25(24):3746- 3752. (Pubitemid 47372616)
14. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6(6): 931-933.
15. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players lymphocytes involved in the crosstalk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339-2346. (Pubitemid 351451442)
16. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25-30.
17. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005; 65(13):5516-5519. (Pubitemid 40911150)
18. Plattel WJ, Van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica. 2012; 97(3):410-415.
19. MacManus MP, Seymour J, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10-18. (Pubitemid 47559835)
20. Kostakoglu L. Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2008;35(8):1413-1420.
21. Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica. 2010; 95(7):1-3.
22. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med. 2008;49(1):13-21.
23. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115(4):793-800. (Pubitemid 34042895)
24. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 1988;6(6):940-946.
25. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429-433. (Pubitemid 29323856)
26. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799.
27. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 2007;78(3):206-212.
28. Girinsky T, Ghalibafian M, Bonniaud G, et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol. 2007;85(2):178-186. (Pubitemid 350160993)
29. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111(6):2977-2983.
30. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916-1927. (Pubitemid 350074687)
31. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. J Clin Oncol. 2006;24(19):3128-3135. (Pubitemid 46638951)
32. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003; 21(19):3601-3608. (Pubitemid 46594052)
33. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol. 2005;23(21):4574-4576. (Pubitemid 46224056)
34. Yahalom J. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol. 2006; 24(4):544-548. (Pubitemid 46630415)
35. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
36. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
37. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-4642. (Pubitemid 46237440)
38. Kostakoglu L, Schöder H, Johnson JL, et al. Interim FDG PET imaging in stage I/II bon-bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk Lymphoma. 2012;53(11):2143-2150.
39. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23(30)7555-7564. (Pubitemid 46291819)
40. Gallamini A, Bianchi A, Borra A, et al. Dual-point FDG-PET: a novel scanning technique in Hodgkin lymphoma with bulky disease. J Clin Oncol. 2012; 30(Suppl):8077.
41. Tailored therapy for Hodgkin lymphoma using early interim therapy PET for therapy decision. http://www.clinicaltrials.gov/ct2/show/ NCT00392314. Accessed August 3, 2012.
42. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or II Hodgkin's lymphoma (EORTC/GELA/FIL). http://clinicaltrials.gov/ct2/ show/NCT00433433. Accessed August 3, 2012.
43. Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma. http://clinicaltrials. gov/ct2/show/NCT01118026. Accessed August 3, 2012.
44. Chemotherapy based on PET scan in treating patients with stage I or stage II Hodgkin lymphoma (ECOG). http://www.clinicaltrials.gov/ct2/ show/NCT01390584. Accessed August 3, 2012.
45. Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma (CALGB 50604). http://www.clinicaltrials.gov/ct2/show/ NCT01132807. Accessed August 3, 2012.
46. PET scan in planning treatment in patients undergoing combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma. http://clinicaltrials. gov/ct2/show/NCT00943423. Accessed August 3, 2012.
47. HD16 for early stage Hodgkin lymphoma. http:// clinicaltrials.gov/ct2/ show/NCT00736320. Accessed August 3, 2012.
48. HD17 for intermediate stage Hodgkin lymphoma. http://www.clinicaltrials. gov/ct2/show/ NCT01356680. Accessed August 3, 2012.
49. André M, Reman O, Fédérico M, Brice P, et al. First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). Blood. 2009;114:97.
50. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009; 20(11):1848-1853.
51. Radford J, O'Doherty M, Barrington S, Qian W, Popova B, Pettengl R. Results of the 3rd planned interim analysis of the UK NCRI RAPID Trial (Involved field radiotherapy versus no further treatment) in patients with clinical stage IA/IIA Hodgkin Lymphoma and a "negative" 18FDG-PET scan after 3 cycles of ABVD. Haematologica. 2010;95:P059.
52. Gallamini A, Barrington S, Biggi A, et al. International Validation Study of interpretation rules and prognostic role of interim-PET scan in advanced-stage Hodgkin Lymphoma. Ann Oncol. 2011;22(Suppl 4):O47.
53. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL) (HD0607). http://www.clinicaltrials.gov/ct2/ show/NCT00795613. Accessed August 3, 2012.
54. Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma (SWOG-CALG-B). http://clinicaltrials.gov/ct2/ show/NCT00822120. Accessed August 3, 2012.
55. Study of a treatment driven by early PET response to a treatment not monitored by early PET in patients with AA stage 3-4 or 2B HL (AHL 2011). http://clinicaltrials.gov/ct2/show/ NCT01358747. Accessed August 3, 2012.
56. Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma (RATHL). http://www.clinicaltrials. gov/ct2/show/NCT00678327. Accessed August 3, 2012.
57. HD18 for advanced stages in Hodgkin's lymphoma. http://clinicaltrials. gov/ct2/show/ NCT00515554. Accessed August 3, 2012.
58. High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD (HD0801) and comparison of RT versus no RT in PET-2 negative patients (HD0802). http://www.clinicaltrials.gov/ct2/show/ NCT00784537. Accessed August 3, 2012.
59. Tailored therapy for Hodgkin lymphoma using early interim therapy PET for therapy decision. http://clinicaltrials.gov/ct2/show/NCT00392314. Accessed August 3, 2012.
60. Gallamini A, O'Doherthy M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma. 2011;52(4):583-586.
61. Gallamini A, Tarella C, Patti C, et al. Multicentre Clinical Study with early treatment intensification in high-risk Hodgkin Lymphoma (HL) patients with a positive FDG-PET scan after twoABVD courses: GITIL HD0607 study. Ann Oncol. 2011;22(Suppl 4): O167.
62. Ziakas PD, Poulou LS. Improving outcome after positive interim PET in advanced Hodgkin's disease: reality vs expectation. Eur J Nucl Med Mol Imaging. 2008;35(8):1573-1575.
63. Kasamon Y. Prognostication and risk-adapted therapy of Hodgkin's lymphoma using positron emission tomography. Adv Hematol. 2011; 271595:1-12.
64. Gallamini A, Patti C, Viviani S, et al. Gruppo Italiano Terapie Innovative ne nei Linfomi (GITIL): early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after twoABVD courses. Br J Haematol. 2011;152(5):551-560.
65. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109(3):905-909. (Pubitemid 46220633)
66. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011:317-322.
67. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.
68. Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010;51(12):2171-2180.
69. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53(1):1876-1881.
70. Barrington S, Qian W, Somer EJ, et al. Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-1833.
71. Biggi A, Barrington S, Hutchings M, et al. Analysis of the Deauville criteria for the assessment of interim PET in advanced stage Hodgkin Lymphoma patients enrolled in the IVS study: II. Reliability of score and concordance among reviewers. J Nucl Med. 2012;53(1)154. Abstract 506.
72. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. (Pubitemid 350002965)
73. Dann EJ, Bar-Shalom R, Tamir A, et al. A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18- fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. Haematologica. 2010;95(7):1198-1206.
74. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1): 37-43.
75. Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease. Eur J Radiol. 2009;70(3):499-506.
76. 18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30(5):682-688.
77. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44(4):540-548. (Pubitemid 39663420)
78. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9): 1721-1727. (Pubitemid 47386707)
79. Savage KJ, Connors JM, Klasa RJ, et al. The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol. 29: 2011(Suppl):8034.
80. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant. 1997;20(1):21-26. (Pubitemid 27341598)
81. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28(34): 5074-5080.
82. Poulou LS, Thanos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging. 2010;37(1):156-162.
83. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory. Blood. 2010;116(23):4934-4937.
84. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012; 119(7):1665-1670.
85. Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145(3):369-372.
86. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
87. Brentuximab Vedotin (SGN-35) in transplant eligible patients with relapsed or refractory Hodgkin lymphoma. http://clinicaltrials.gov/ct2/show/ NCT01508312. Accessed August 3, 2012.
88. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med. 2006;47(4):603-608. (Pubitemid 46768461)
89. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.
90. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009; 7(Suppl 2):S1-S26.
91. Gallamini A, Barrington S, Biggi A, et al. International validation study of interpretation rules and prognostic role of interim-PET scan in advancedstage Hodgkin Lymohoma. Ann Oncol. 2011; 22(Suppl 4):Abstract 047.